comparemela.com

Targeting Chimeras News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Needle Tracking System Market: Ensuring Accuracy and Driving

Nuclear Pharmacy Market: Delivering Targeted Therapies

PerkinElmer supports PROXIDRUGS consortium to address disease-relevant human proteins

PerkinElmer supports PROXIDRUGS consortium to address disease-relevant human proteins PerkinElmer supports PROXIDRUGS consortium to address disease-relevant human proteins 26 April 2021 | News Photo Credit: Freepik PerkinElmer, Inc., announced that it is serving as a provider and co-developer of assays, instrument solutions and expertise for the PROXIDRUGS Consortium which is zeroing in on research for proximity drugs or PROTACs (PROteolysis Targeting Chimeras).  PROTACs are a new class of drugs that take advantage of the body’s own cell protein recycling system to fight disease by tapping into the 80% of disease-relevant proteins that are currently untargeted by today’s available therapeutics.    The research project, starting October 2021, aims to streamline novel drug target validation by putting disease-relevant proteins in close proximity with key enzymes (such as E3 ligases) so that they can be marked for destruction and recycled by the cells’ natural shr

PerkinElmer, Inc : PerkinElmer Supports PROXIDRUGS Consortium Aimed at Advancing Targeted Protein Degradation/PROTAC Drugs

PerkinElmer, Inc.: PerkinElmer Supports PROXIDRUGS Consortium Aimed at Advancing Targeted Protein Degradation/PROTAC Drugs Leading academic and industry cluster to help address 80% of disease-relevant human proteins currently undruggable PerkinElmer, Inc., a global leader committed to innovating for a healthier world, today announced that it is serving as a provider and co-developer of assays, instrument solutions and expertise for the PROXIDRUGS Consortium which is zeroing in on research for proximity drugs or PROTACs (PROteolysis Targeting Chimeras). PROTACs are a new class of drugs that take advantage of the body s own cell protein recycling system to fight disease by tapping into the 80% of disease-relevant proteins that are currently untargeted by today s available therapeutics. Led by Goethe University in Frankfurt, Germany, the Consortium includes researchers from the Technical University of Darmstadt, the Fraunhofer Institute for Translational Medicine and Pharmacology

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.